Therapeutic Solutions International Returns to Fully Reporting Status with SEC
July 06 2017 - 9:00AM
InvestorsHub NewsWire
OCEANSIDE, CA-(Marketwired – July 6, 2017) - Therapeutic
Solutions International, Inc. (OTC: TSOI),
announced today that it has recently completed all of its
regulatory filings to return to fully reporting status required by
the Securities and Exchange Commission (SEC).
"We are excited to have achieved this milestone for the company.
Since April of 2016 we were able to file with the SEC four Annual
Reports on Form 10-K, and ten Quarterly Reports on Form 10-Q going
back to December 2013 and current to March 2017, stated Tim Dixon,
CEO of Therapeutic Solutions International, Inc. This will
give shareholders, investors, and the general public greater access
to timely information on the Company. We also look forward to
being upgraded to a higher tier on the OTC Markets in the near
future.”
Additionally, during this time we have also been able to launch
three new subsidiaries; (1) Emvolio, Inc., (www.emvolio.com)
focused on Immune-Oncology; (2) OmniBiome, Inc., (www.omnibiomeinc.com) focused on
Fetal-Maternal Health; (3) and SandBox Dental Labs, Inc. (sandbox.dental) focused on
Obstructive Sleep Apnea with our Sleep Apnea appliance named
“Morpheus™”.
“TSOI has also filed twelve new Patents with the U.S. Patent and
Trademark Office. Our first patent filed on ProJuvenol in July 2015
has just been granted US Patent No. 9,682,047 on June 20, 2017.
This patent covers various combinations of pterostilbene with
immunotherapeutics for the purpose of augmenting efficacy in both
the stimulation of immune killer cells, as well as immune cells
that reduce growth of cancer cells. We were very pleased to also
announce that in April 2017, Emvolio filed an New Investigational
Drug Application with the FDA for our cancer vaccine “StemVacs” and
SandBox Dental just announced on June 26 that they had filed a
premarket 510(k) notification with the US FDA for “Morpheus™” our
sleep apnea appliance added Tim Dixon, CEO of Therapeutic Solutions
International, Inc.
About Therapeutic Solutions International,
Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
Our new products can be viewed on www.projuvenol.com and products
can be ordered at www.youcanordernow.com.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024